论文部分内容阅读
据英国St Mary医院医学院和Charing Cross医院的研究者说,在非甲非乙型肝炎(NANBH)病人中,小剂量α干扰素可稳定肝脏酶并预防其发展为慢性肝病。他们在14例转氨酶活性持续增高6个月以上、组织学证实为符合NANBH的慢性肝炎并排除其他原因的成年患者中进行一项前瞻性随机试验。除2例外,所有病例均经胃肠道外接触血液或血液制品后发生NANBH。7例接受每周3次、每次5MU干扰素治
According to researchers at St Mary’s Hospital College of Medicine and Charing Cross Hospital in the United Kingdom, low-dose interferon alpha stabilizes liver enzymes and prevents them from developing chronic liver disease in non-A, non-B hepatitis (NANBH) patients. They conducted a prospective randomized trial in 14 adult patients with persistent aminotransferase activity over 6 months histologically confirmed as NANBH-associated chronic hepatitis and for other reasons. With all but 2 exceptions, NANBH occurred in all cases after parenteral exposure to blood or blood products. Seven patients received three times weekly, each 5MU interferon treatment